Welcome to our dedicated page for Century Therapeutics SEC filings (Ticker: IPSC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Century Therapeutics, Inc. filings document a biotechnology issuer developing iPSC-derived cell therapy programs for autoimmune diseases and cancer, along with the formal records supporting its public-company governance and capital structure. Form 8-K reports include operating and financial results, Regulation FD investor-presentation materials, clinical and regulatory program disclosures, and board composition changes.
Proxy and shareholder-vote materials cover annual meeting matters, board and committee governance, and charter-amendment voting, including reverse-stock-split authority. Capital-structure filings include shelf registration and at-the-market equity offering disclosures for common stock, while cover-page disclosures identify Century as an emerging growth company.
Century Therapeutics director Martin Patrick Murphy received a grant of stock options as part of his compensation. He was awarded options covering 74,000 shares of common stock at an exercise price of $2.24 per share, expiring on June 11, 2036.
The option vests on the earlier of June 11, 2027 or the next annual meeting of stockholders, subject to his continued service through the vesting date. Following this grant, he holds options for 74,000 shares directly, with no open-market buying or selling reported in this filing.
Century Therapeutics, Inc. reported that director Lee Han Myung received a grant of stock options covering 74,000 shares of common stock. The options have an exercise price of $2.24 per share and expire on June 11, 2036.
The option award vests on the earlier of June 11, 2027 or the company’s next annual meeting of stockholders, in each case only if Lee Han Myung continues to serve through the vesting date. Following this grant, the filing shows holdings of 74,000 stock options directly.
Century Therapeutics director Kimberly Blackwell received a stock option grant for 74,000 shares of common stock. The option has an exercise price of $2.24 per share and expires on June 11, 2036. All 74,000 options vest on the earlier of June 11, 2027 or the next annual stockholder meeting, subject to her continued service.
Century Therapeutics, Inc. increased the number of authorized shares of its common stock from 300,000,000 to 450,000,000 through a Certificate of Amendment that became effective on June 12, 2026. Stockholders approved this Authorized Shares Amendment at the company’s 2026 Annual Meeting.
At the same meeting, stockholders elected Alessandro Riva, M.D. and Han Lee, Ph.D., M.B.A. as Class II directors, each to serve until the 2029 Annual Meeting. They also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the 2026 fiscal year and approved an adjournment proposal, although an adjournment was not needed.
IPSC reported Form 144 notice covering sale transactions by an insider. The filing lists 2,584 shares as the securities to be sold and records prior dispositions of 10,076 shares on 03/12/2026 and 524 shares on 06/08/2026. The sale method is labeled "Restricted Stock Vesting" and the filing identifies Fidelity Brokerage Services LLC as the broker.
Century Therapeutics, Inc. insider Gregory Russotti reported an automatic sale of shares to cover taxes on vesting stock awards. The Form 4 shows a sale of 524 shares of common stock at $2.111 per share, which a footnote explains was required to cover tax withholding obligations from vesting restricted stock units and was not at his discretion.
After this transaction, Russotti holds 514,903 shares of Century Therapeutics common stock directly and 92,773 shares indirectly through the Gregory Russotti 2021 Family Trust, indicating the tax-related sale is small relative to his overall position.
Century Therapeutics SVP Finance & Operations Douglas Carr reported a small automatic sale of 249 shares of common stock. The shares were sold on June 8, 2026 at $2.111 per share to cover tax withholding obligations tied to vesting restricted stock units. According to the filing, these sales were automatic and not at Carr’s discretion. After the transaction, he directly holds 506,748 shares of Century Therapeutics common stock.
Century Therapeutics, Inc. President and CEO Brent Pfeiffenberger reported a small share disposition related to taxes. On the vesting of restricted stock units, 463 shares of Common Stock were withheld by the company at a price of $2.13 per share to cover tax withholding obligations, leaving him with 3,679,323 shares held directly.
Century Therapeutics filed an 8-K after presenting new preclinical data for CNTY-813, its iPSC-derived islet replacement therapy for type 1 diabetes, at the American Diabetes Association 2026 Scientific Sessions. CNTY-813 uses the company’s Allo-Evasion™ 5.0 immune evasion technology.
In diabetic mouse models, CNTY-813 islet cells rapidly restored normal blood sugar and maintained glucose control for more than eight months, with glucose normalization within 60 minutes on tolerance testing. Safety data showed stable graft morphology, no abnormal outgrowth, and no tumorigenesis across over 140 mice infused with one billion cells.
The company also reported strong in vitro and in vivo immune protection, including preserved C-peptide secretion and glucose tolerance in a humanized allogeneic rejection model, and consistent product quality from its Phase 1 manufacturing process. Century is targeting an IND submission for CNTY-813 in the fourth quarter of 2026 and anticipates initial clinical data in the second half of 2027.
IPSC filed a Form 144 notice proposing the sale of Common stock tied to a Restricted Stock Vesting event on 06/05/2026. The filing also lists prior sales by Gregory Russotti: 479 shares on 03/09/2026 (listed with $1,214.98) and 10,076 shares on 03/12/2026 (listed with $25,685.74). The broker/dealer named is Fidelity Brokerage Services LLC.